A Trial In Patients With Advanced Cancer And Leukemia

Pfizer

Status and phase: Completed; Phase 1

Conditions: Neoplasms by Histologic Type

Treatments: Drug: PF-03084014

Study type: Interventional

Funder types: Industry

Identifiers

NCT00878189

A8641014

2010-022036-36 (EudraCT Number)

Details and patient eligibility

About

This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia

Enrollment: 72 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with advanced cancer that is resistant to standard therapy or for which no standard therapy is available
• Patients with acute T cell leukemia/lymphoblastic lymphoma that is resistant to standard therapy or for which no standard therapy is available
• Men and women >16 years old

Exclusion criteria

• Prior treatment with a gamma secretase inhibitor for treatment of cancer
• Patients taking Tamoxifen
• Patients with active graft versus host disease
• Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
• Patients who are pregnant or breast feeding
• Patients with clinical evidence of central nervous system disease

Trial design

72 participants in 1 patient group

1

Experimental group

Treatment:

Drug: PF-03084014